Coya Therapeutics
Market cap $70.8M 23.5M shares (10-Q, Nov 5, 2026) × $3.02 close Nov 17, 2026
Most recent annual filing: 2026-03-16
- MediciNova ibudilast ALS topline2026MediciNova ibudilast ALS topline, 2026, material
- COYA pipeline biomarkers readout2H 2026COYA pipeline biomarkers readout, 2H 2026, notable
- COYA 302 FTD Ph2 start2H 2026COYA 302 FTD Ph2 start, 2H 2026, routine
- DRL_AB FDA approvalLate 2026DRL_AB FDA approval, Late 2026, material
- Clene CNM-Au8 NDA filing4Q 2026Clene CNM-Au8 NDA filing, 4Q 2026, notable
- COYA 302 ALS corporate updateNov 2026COYA 302 ALS corporate update, Nov 2026, notable
- COYA corporate manufacturing updateNov 2026COYA corporate manufacturing update, Nov 2026, routine
- COYA 302 ALS corporate update~Mar 2027COYA 302 ALS corporate update, ~Mar 2027, notable
- COYA 302 ALS toplineearly 2Q 2027COYA 302 ALS topline, early 2Q 2027, thesis-defining
- RAPA-501 Ph2/3 readoutJul 2027RAPA-501 Ph2/3 readout, Jul 2027, notable
- COYA corporate financing2H 2027COYA corporate financing, 2H 2027, routine
- COYA 302 ALS corporate update~Sep 2027COYA 302 ALS corporate update, ~Sep 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
COYA 301
- Undisclosed indication
COYA 303
- Undisclosed indication
COYA 201
- Undisclosed indication
COYA 206
- Undisclosed indication
Technology platforms
Treg-derived exosomes
Treg-derived exosome platform leveraging exosomes from regulatory T cells; focus areas include neurodegenerative, autoimmune, and metabolic diseases
Targets: Treg
Discontinued (1)
- autologous Treg cell therapy — Amyotrophic Lateral Sclerosis · deprioritised: Coya's priority is COYA 302 in ALS and FTD; no COYA 101 development since the 2022 S-1
Capital (as filed)
- Cash
- $35.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$7.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $35.8M cash, runway second half of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-11 UPDATE: Coya Therapeutics (COYA) - The Going-Concern Flag and the Staggered Dose 🔒 Paid
- 2026-10-15 Coya Therapeutics (COYA) - Scientific Deep Dive for COYA 302 (Low-Dose IL-2 + CTLA-4 Ig) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Coya Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-15 Avoid Coya Therapeutics (COYA) - Scientific Deep Dive for COYA 302 (Low-Dose IL-2 + CTLA-4 Ig) and Pipeline Products COYA 302 attaches real Treg pharmacology to a four-patient signal carried by one outlier, a trial underpowered for Radicava-sized effects, and a royalty structure leaving Coya only ~6–12% of ALS sales, making the binary fairly priced at ~$98M with no edge.
- 2026-11-11 Avoid UPDATE: Coya Therapeutics (COYA) - The Going-Concern Flag and the Staggered Dose New going-concern warning, faster burn reducing cash-at-readout to ~$0.45–0.60/share, and a staggered-dose disclosure in the low-dose arm raise design ambiguity and dilution risk, keeping the binary unattractive at $3.16.
- Avoid call · opened Oct 15, 2026 at $4.34 · -30.4% vs XBI -3.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
““With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”
matched to COYA 302 (ALS) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 14, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseCoya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateCOYA's Q3 burn rate surged to ~$10M — well above the $7.5M/quarter assumption in the original PASS verdict — compressing the cash cushion at the ALSTARS readout and triggering a formal going-concern disclosure for the first time. The 137-patient final enrollment (vs. 120 planned) is a mild bright spot for statistical power, but it's not enough to offset the burn acceleration.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 28, 2026ReleaseCoya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual
- Oct 14, 2026ReleaseCoya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSvia aggregator
- Oct 14, 20268-KCurrent report: other events
- Oct 5, 20268-KCurrent report: other events
- Sep 15, 20268-KCurrent report: other events
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Aug 7, 20268-K/ACurrent report (amended): officer / director change
- Jun 25, 20268-KCurrent report: shareholder vote
- May 13, 2026DEFA14AProxy soliciting material
- May 13, 2026DEF 14AProxy statement
- May 12, 20268-KCurrent report: material agreement
- May 12, 20268-KCurrent report: results of operations, other events · EX-99.1
- May 12, 2026424B5Prospectus supplement (offering)
- May 12, 202610-QQuarterly report
- Apr 2, 20268-KCurrent report: officer / director change · EX-99.1
- Mar 20, 2026424B3Prospectus (resale / update)
- Mar 16, 2026S-3Shelf registration
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026ARSAnnual report to shareholders
- Mar 20, 2026EFFECTRegistration effective
- Mar 19, 2026UPLOADUPLOAD
- Mar 19, 2026CORRESPCORRESP
- Mar 12, 2026SCHEDULE 13GPassive >5% holder (13G)